Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

CNS Stimulants: Psychedelic Agents01:22

CNS Stimulants: Psychedelic Agents

258
Hallucinogens, also known as psychedelic drugs, are a class of substances known for their ability to alter perception, cognition, and emotions. Despite their profound effects on the mind, these drugs are non-addictive, setting them apart from many other abused substances. The mechanism of action of these drugs lies in their impact on the 5-HT2A receptor in the brain. Upon activation, this receptor couples to Gq-type G proteins, triggering a cascade that releases intracellular calcium. This...
258
Hallucinogens and Psychedelics01:27

Hallucinogens and Psychedelics

296
Hallucinogens are psychoactive substances that profoundly alter perceptual experiences, generating unreal visual and sensory images. Often referred to as psychedelic drugs — a term derived from the Greek words "psyche" (mind) and "delos" (revealing) — these substances include marijuana and lysergic acid diethylamide (LSD), among others. These drugs vary in intensity and effects.
Marijuana, derived from the dried leaves and flowers of the hemp plant, contains...
296
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

383
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
383
Drug Therapy01:28

Drug Therapy

107
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
107
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

219
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
219
Psychodynamic Therapy01:29

Psychodynamic Therapy

152
Psychodynamic therapies emphasize the exploration of unconscious processes and early childhood experiences as fundamental contributors to psychological difficulties. These therapies, deeply rooted in Freud's psychoanalytic theory, aim to uncover and resolve unconscious conflicts, granting individuals insights that promote emotional and behavioral healing. Contemporary psychodynamic approaches have evolved, integrating a broader range of influences and methodologies while still valuing the...
152

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A systematic review of the pharmacokinetics of classical serotonergic psychedelic compounds in healthy adult subjects.

Journal of psychopharmacology (Oxford, England)·2026
Same author

Pharmacological augmentation for people with treatment-resistant depression.

The British journal of psychiatry : the journal of mental science·2026
Same author

Characterising the clinical associations of hallucinogen persisting perception disorder: a retrospective cohort study.

Translational psychiatry·2026
Same author

A phase 2 uncontrolled, open-label study of intranasal BPL-003 (5-methoxy-<i>N,N</i>-dimethyltryptamine) in patients with treatment-resistant depression.

Journal of psychopharmacology (Oxford, England)·2026
Same author

Effects of psilocybin on personality, psychiatric symptoms, and values: Exploring mediating effects of the acute psychedelic experience.

Journal of psychopharmacology (Oxford, England)·2026
Same author

Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trial.

Journal of psychopharmacology (Oxford, England)·2025

Related Experiment Video

Updated: Sep 21, 2025

Using a Murine Model of Psychosocial Stress in Pregnancy as a Translationally Relevant Paradigm for Psychiatric Disorders in Mothers and Infants
06:39

Using a Murine Model of Psychosocial Stress in Pregnancy as a Translationally Relevant Paradigm for Psychiatric Disorders in Mothers and Infants

Published on: June 13, 2021

3.2K

Postpartum depression: A role for psychedelics?

Chaitra Jairaj1,2, James J Rucker1,3

  • 1Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.

Journal of Psychopharmacology (Oxford, England)
|May 31, 2022
PubMed
Summary
This summary is machine-generated.

Serotonin psychedelics show promise for treating postpartum depression (PPD) by fostering maternal reconnection. Further research is needed to explore psychedelic-assisted therapy for the mother-infant relationship.

Keywords:
Mother–infant relationshippostpartum depressionpsilocybinpsychedelics

More Related Videos

Using Chronic Social Stress to Model Postpartum Depression in Lactating Rodents
07:30

Using Chronic Social Stress to Model Postpartum Depression in Lactating Rodents

Published on: June 10, 2013

25.0K
Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression
07:58

Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression

Published on: February 24, 2023

598

Related Experiment Videos

Last Updated: Sep 21, 2025

Using a Murine Model of Psychosocial Stress in Pregnancy as a Translationally Relevant Paradigm for Psychiatric Disorders in Mothers and Infants
06:39

Using a Murine Model of Psychosocial Stress in Pregnancy as a Translationally Relevant Paradigm for Psychiatric Disorders in Mothers and Infants

Published on: June 13, 2021

3.2K
Using Chronic Social Stress to Model Postpartum Depression in Lactating Rodents
07:30

Using Chronic Social Stress to Model Postpartum Depression in Lactating Rodents

Published on: June 10, 2013

25.0K
Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression
07:58

Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression

Published on: February 24, 2023

598

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Postpartum depression (PPD) is a significant public health issue characterized by maternal disconnection.
  • PPD shares similarities with major depressive disorder (MDD) but has distinct features, particularly concerning the mother-infant relationship.
  • Current PPD treatments, adapted from MDD therapies, exhibit low remission rates and increasing treatment resistance, necessitating alternative approaches.

Purpose of the Study:

  • To review the therapeutic potential of serotonergic psychedelics for PPD.
  • To examine the safety and practical considerations of using psychedelics during the postpartum period.

Main Methods:

  • A narrative review of existing evidence for PPD treatment.
  • Review of studies on psychedelic use in MDD treatment.
  • Exploration of safety data for postpartum psychedelic use.

Main Results:

  • Psilocybin demonstrates increasing evidence of safety and efficacy in MDD treatment.
  • Psilocybin has been observed to promote a sense of 'reconnection' in individuals with MDD.
  • In PPD, this 'reconnection' effect could enhance maternal mood and sensitivity, improving maternal satisfaction and the mother-infant bond.

Conclusions:

  • Psychedelic-assisted therapy presents a potential avenue for improving the mother-infant dyad in PPD.
  • Further investigation into psychedelic-assisted therapy for PPD is warranted.